Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint
(Reuters) - Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Lung Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Study | Taxotere